[Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
Heslet
Lars
L
Koagulationsiaboratoriet, H:S Rigshospitalet, Intensivafdeling ITA 4131, Amtssygehuset i Gentofte. heslet@rh.dk
Nielsen
Jørn Dalsgaard
JD
Schierbeck
Jens
J
Andersen
Jakob Steen
JS
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000075202:Contraindications; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008991:Monitoring, Physiologic; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D018805:Sepsis / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index
D000890:Anti-Infective Agents; D005343:Fibrinolytic Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated